Inosine

Inosine

Clinical data
ATC code	D06BB05 (WHO) G01AX02 (WHO)
Pharmacokinetic data
Metabolism	Hepatic
Identifiers
IUPAC name Inosine
CAS Number	58-63-9
PubChem CID	6021
DrugBank	EXPT02378
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C10H12N4O5
Molar mass	268.229 g/mol

WikiDoc Resources for Inosine
Articles
Most recent articles on Inosine Most cited articles on Inosine Review articles on Inosine Articles on Inosine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Inosine Images of Inosine Photos of Inosine Podcasts & MP3s on Inosine Videos on Inosine
Evidence Based Medicine
Cochrane Collaboration on Inosine Bandolier on Inosine TRIP on Inosine
Clinical Trials
Ongoing Trials on Inosine at Clinical Trials.gov Trial results on Inosine Clinical Trials on Inosine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Inosine NICE Guidance on Inosine NHS PRODIGY Guidance FDA on Inosine CDC on Inosine
Books
Books on Inosine
News
Inosine in the news Be alerted to news on Inosine News trends on Inosine
Commentary
Blogs on Inosine
Definitions
Definitions of Inosine
Patient Resources / Community
Patient resources on Inosine Discussion groups on Inosine Patient Handouts on Inosine Directions to Hospitals Treating Inosine Risk calculators and risk factors for Inosine
Healthcare Provider Resources
Symptoms of Inosine Causes & Risk Factors for Inosine Diagnostic studies for Inosine Treatment of Inosine
Continuing Medical Education (CME)
CME Programs on Inosine
International
Inosine en Espanol Inosine en Francais
Business
Inosine in the Marketplace Patents on Inosine
Experimental / Informatics
List of terms related to Inosine

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Inosine is a nucleoside that is formed when hypoxanthine is attached to a ribose ring (also known as a ribofuranose) via a β-N₉-glycosidic bond.

Inosine is commonly found in tRNAs and is essential for proper translation of the genetic code in wobble base pairs.

Knowledge of inosine metabolism has led to advances in immunotherapy in recent decades. Inosine monophosphate is oxidised by the enzyme inosine monophosphate dehydrogenase yielding xanthosine monophosphate, a key precursor in purine metabolism. Mycophenolate mofetil is an anti-metabolite, anti-proliferative drug, used in the treatment of a variety of autoimmune diseases including Wegener's granulomatosis. The uptake of purine by actively dividing B cells can exceed 8 times that of normal body cells and therefore this set of white cells (which cannot operate purine salvage pathways) is selectively targeted by the purine deficiency resulting from IMD inhibition.

Reactions

Adenine is converted to adenosine or IMP, either of which in turn is converted into inosine (I), which pairs with adenine (A), cytosine (C) and uracil (U).

Purine nucleoside phosphorylase intraconverts inosine and hypoxanthine.

Inosine is also an intermediate in a chain of purine nucleotides reactions required for muscle movements.

Clinical significance

It was tried in the seventies in eastern countries for improving athletic performance, based on the fact that is an intermediate compound used in the muscle movements. Nevertheless the clinical trials with this purpose showed no improvement.

Nowadays, it has been shown that inosine has neuroprotective properties. It has been proposed for administration after stroke, because observation has shown that axonal re-wiring is encouraged. It has been tried also for multiple sclerosis and is currently in phase II of the trials [2].

It produces uric acid after ingestion, which is a natural antioxidant and a peroxinitrite scavenger, which can explain the behaviour in multiple sclerosis [3](peroxynitrite has been correlated with the axons degeneration [4]).

Currently Boston Life Sciences holds the patent for treatment of stroke [5] and this company is currently investigating its properties for MS under the name axosine for Multiple Sclerosis.

Biotechnology

When designing primers for polymerase chain reaction, inosine is useful in that it will indiscriminately pair with adenine, thymine, or cytosine. This allows one to design a primer that spans a single nucleotide polymorphism, without worry that the polymorphism will disrupt the primer's annealing efficiency.

External links

• PDR health study